Overview

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Status:
Completed

Trial end date:
2013-01-01

Target enrollment:

Participant gender:

Summary

This study will investigate the efficacy of both low and high doses of methotrexate (MTX) in combination with open-label adalimumab (ADA) in patients who have had an inadequate response to high dose of MTX. The study will also evaluate the pharmacokinetics and safety of the two regimens of MTX in combination with ADA in participants with rheumatoid arthritis (RA).

Phase:

Phase 4

Details

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Treatments:

Adalimumab
Methotrexate